Investigational New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted Without an IND: Guidance for Clinical Investigators, Sponsors, and IRBs
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
September 10, 2013
October 1, 2024
83e34c5d-552a-445c-81e3-be44082f30a8
Related Documents
IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed: Guidance for IRBs, Clinical Investigators, and Sponsors
Guidance DocumentAugust 27, 2013Office of the Commissioner
Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry
Guidance DocumentApril 12, 2011Center for Drug Evaluation and Research
Labeling for Human Prescription Drug and Biological Products — Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information
Guidance DocumentOctober 19, 2009Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.